Join to View Full Profile
300 Pasteur DrFl 1Stanford, CA 94305
Phone+1 650-723-4000
Are you Dr. Pegram?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Mark Pegram, MD is an oncologist in Stanford, California. He is currently licensed to practice medicine in California, Florida, and Texas. He is a Professor at Stanford University Sch of Med.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1986 - 1989
University of North Carolina at Chapel Hill School of MedicineClass of 1986
Certifications & Licensure
CA State Medical License 1989 - 2026
FL State Medical License 2008 - 2012
TX State Medical License 1989 - 1990
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsImpact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study.Tara B Sanft, Jenna Wong, Brandon O'Neal, Natalia Siuliukina, Rachel C Jankowitz
Journal of the National Comprehensive Cancer Network. 2024-03-04 - 8 citationsPertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data.Nancy U Lin, Priya Kumthekar, Solmaz Sahebjam, Nuhad Ibrahim, Anita Fung
NPJ Breast Cancer. 2023-11-17 - 10 citationsIncorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer.Giuseppe Curigliano, Rebecca Dent, Antonio Llombart-Cussac, Mark Pegram, Lajos Pusztai
NPJ Breast Cancer. 2023-06-28
Press Mentions
Meet 7 Femtech Companies Innovating in the Area of Ovarian Health, Breast and Gynecological CancersMarch 16th, 2022- Clinical Picture Brightens for HER2+ Breast Cancer with Brain MetastasesMarch 7th, 2022
- Cedars-Sinai, Rubedo Partner to Develop Targeted IPF TreatmentsJune 8th, 2021
- Join now to see all
